RFK pick poses uncertainty in areas of healthcare sector, says Wolfe Research's Marcus Tobin
Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...
Wolfe Research Upgrades Warner Bros. Discovery as Max Sees Improvement
Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Veracyte initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...
Wolfe upgrades Warner Bros. Discovery as trends at Max improve
Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...
bovnews1d
Solid Power Inc (SLDP) Reported a -587.71% Operating Margin Last Year—What’s the Real Story?
On Friday, Solid Power Inc (SLDP) stock saw a decline, ending the day at $1.02 which represents a decrease of $-0.04 or -3.77% from the prior close of $1.06. The stock opened at $1.05 and touched a ...
bovnews1d
Analysts Predict a $130 Target for TransUnion (TRU) Stock—What Could Drive It There?
On Friday, TransUnion (TRU) stock saw a decline, ending the day at $95.66 which represents a decrease of $-3.74 or -3.76% from the prior close of $99.4. The stock opened at $98.13 and touched a low of ...
Warner Bros. Discovery stock upgraded at Wolfe on re-bundling trends
Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ: NASDAQ: WBD) to Peer Perform from ...
Nasdaq6d
Alnylam cut to Underperform at Wolfe Research amid Amvuttra expansion
Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...
Nasdaq5d
Wolfe Research Downgrades Alnylam Pharmaceuticals (LSE:0HD2)
Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...